Phosphodiesterase	B:C1452465
10A	I:C1452465
Inhibition	O
Improves	O
Cortico-	O
Basal	I:C0004781
Ganglia	I:C0004781
Function	O
in	O
Huntington	O
's	I:C0020179
Disease	I:C0020179
Models	O
.	O

Phosphodiesterase	O
10A	I:C1452465
Inhibition	O
Improves	O
Cortico-	B:C0004781
Basal	I:C0004781
Ganglia	I:C0004781
Function	O
in	O
Huntington	O
's	I:C0020179
Disease	I:C0020179
Models	O
.	O

Phosphodiesterase	O
10A	I:C1452465
Inhibition	O
Improves	O
Cortico-	O
Basal	I:C0004781
Ganglia	I:C0004781
Function	B:C0031843
in	O
Huntington	O
's	I:C0020179
Disease	I:C0020179
Models	O
.	O

Phosphodiesterase	O
10A	I:C1452465
Inhibition	O
Improves	O
Cortico-	O
Basal	I:C0004781
Ganglia	I:C0004781
Function	O
in	O
Huntington	B:C0020179
's	I:C0020179
Disease	I:C0020179
Models	O
.	O

Phosphodiesterase	O
10A	I:C1452465
Inhibition	O
Improves	O
Cortico-	O
Basal	I:C0004781
Ganglia	I:C0004781
Function	O
in	O
Huntington	O
's	I:C0020179
Disease	I:C0020179
Models	B:C0012644
.	O

Huntington	B:C0020179
's	I:C0020179
disease	I:C0020179
(	O
Huntington	O
's	I:C0020179
disease	I:C0020179
)	O
symptoms	O
are	O
driven	O
to	O
a	O
large	O
extent	O
by	O
dysfunction	O
of	O
the	O
basal	O
ganglia	I:C0004781
circuitry	O
.	O

Huntington	O
's	I:C0020179
disease	I:C0020179
(	O
Huntington	B:C0020179
's	I:C0020179
disease	I:C0020179
)	O
symptoms	O
are	O
driven	O
to	O
a	O
large	O
extent	O
by	O
dysfunction	O
of	O
the	O
basal	O
ganglia	I:C0004781
circuitry	O
.	O

Huntington	O
's	I:C0020179
disease	I:C0020179
(	O
Huntington	O
's	I:C0020179
disease	I:C0020179
)	O
symptoms	B:C1457887
are	O
driven	O
to	O
a	O
large	O
extent	O
by	O
dysfunction	O
of	O
the	O
basal	O
ganglia	I:C0004781
circuitry	O
.	O

Huntington	O
's	I:C0020179
disease	I:C0020179
(	O
Huntington	O
's	I:C0020179
disease	I:C0020179
)	O
symptoms	O
are	O
driven	O
to	O
a	O
large	O
extent	O
by	O
dysfunction	O
of	O
the	O
basal	B:C0004781
ganglia	I:C0004781
circuitry	O
.	O

Huntington	B:C0020179
's	I:C0020179
disease	I:C0020179
patients	O
exhibit	O
reduced	O
striatal	O
phoshodiesterase	I:C1447737
10	I:C1447737
(	O
phoshodiesterase	O
10	I:C1447737
)	O
levels	O
.	O

Huntington	O
's	I:C0020179
disease	I:C0020179
patients	O
exhibit	O
reduced	O
striatal	B:C1447737
phoshodiesterase	I:C1447737
10	I:C1447737
(	O
phoshodiesterase	O
10	I:C1447737
)	O
levels	O
.	O

Huntington	O
's	I:C0020179
disease	I:C0020179
patients	O
exhibit	O
reduced	O
striatal	O
phoshodiesterase	I:C1447737
10	I:C1447737
(	O
phoshodiesterase	B:C1447737
10	I:C1447737
)	O
levels	O
.	O

Using	O
Huntington	B:C0020179
's	I:C0020179
disease	I:C0020179
mouse	O
models	I:C2986594
that	O
exhibit	O
reduced	O
phoshodiesterase	O
10	I:C1452465
,	O
we	O
demonstrate	O
the	O
benefit	O
of	O
pharmacologic	O
phoshodiesterase	O
10	I:C1452465
inhibition	O
to	O
acutely	O
correct	O
basal	O
ganglia	I:C0004781
circuitry	O
deficits	O
.	O

Using	O
Huntington	O
's	I:C0020179
disease	I:C0020179
mouse	B:C2986594
models	I:C2986594
that	O
exhibit	O
reduced	O
phoshodiesterase	O
10	I:C1452465
,	O
we	O
demonstrate	O
the	O
benefit	O
of	O
pharmacologic	O
phoshodiesterase	O
10	I:C1452465
inhibition	O
to	O
acutely	O
correct	O
basal	O
ganglia	I:C0004781
circuitry	O
deficits	O
.	O

Using	O
Huntington	O
's	I:C0020179
disease	I:C0020179
mouse	O
models	I:C2986594
that	O
exhibit	O
reduced	O
phoshodiesterase	B:C1452465
10	I:C1452465
,	O
we	O
demonstrate	O
the	O
benefit	O
of	O
pharmacologic	O
phoshodiesterase	O
10	I:C1452465
inhibition	O
to	O
acutely	O
correct	O
basal	O
ganglia	I:C0004781
circuitry	O
deficits	O
.	O

Using	O
Huntington	O
's	I:C0020179
disease	I:C0020179
mouse	O
models	I:C2986594
that	O
exhibit	O
reduced	O
phoshodiesterase	O
10	I:C1452465
,	O
we	O
demonstrate	O
the	O
benefit	O
of	O
pharmacologic	O
phoshodiesterase	B:C1452465
10	I:C1452465
inhibition	O
to	O
acutely	O
correct	O
basal	O
ganglia	I:C0004781
circuitry	O
deficits	O
.	O

Using	O
Huntington	O
's	I:C0020179
disease	I:C0020179
mouse	O
models	I:C2986594
that	O
exhibit	O
reduced	O
phoshodiesterase	O
10	I:C1452465
,	O
we	O
demonstrate	O
the	O
benefit	O
of	O
pharmacologic	O
phoshodiesterase	O
10	I:C1452465
inhibition	O
to	O
acutely	O
correct	O
basal	B:C0004781
ganglia	I:C0004781
circuitry	O
deficits	O
.	O

phoshodiesterase	B:C1452465
10	I:C1452465
inhibition	O
restored	O
corticostriatal	O
input	O
and	O
boosted	O
cortically	O
driven	O
indirect	O
pathway	O
activity	O
.	O

phoshodiesterase	O
10	I:C1452465
inhibition	O
restored	O
corticostriatal	B:C0229962
input	O
and	O
boosted	O
cortically	O
driven	O
indirect	O
pathway	O
activity	O
.	O

Cyclic	B:C1155588
nucleotide	I:C1155588
signaling	I:C1155588
is	O
impaired	O
in	O
Huntington	O
's	I:C0020179
disease	I:C0020179
models	O
,	O
and	O
phoshodiesterase	O
10	I:C1452465
loss	O
may	O
represent	O
a	O
homeostatic	O
adaptation	O
to	O
maintain	O
signaling	O
.	O

Cyclic	O
nucleotide	I:C1155588
signaling	I:C1155588
is	O
impaired	O
in	O
Huntington	B:C0020179
's	I:C0020179
disease	I:C0020179
models	O
,	O
and	O
phoshodiesterase	O
10	I:C1452465
loss	O
may	O
represent	O
a	O
homeostatic	O
adaptation	O
to	O
maintain	O
signaling	O
.	O

Cyclic	O
nucleotide	I:C1155588
signaling	I:C1155588
is	O
impaired	O
in	O
Huntington	O
's	I:C0020179
disease	I:C0020179
models	B:C0012644
,	O
and	O
phoshodiesterase	O
10	I:C1452465
loss	O
may	O
represent	O
a	O
homeostatic	O
adaptation	O
to	O
maintain	O
signaling	O
.	O

Cyclic	O
nucleotide	I:C1155588
signaling	I:C1155588
is	O
impaired	O
in	O
Huntington	O
's	I:C0020179
disease	I:C0020179
models	O
,	O
and	O
phoshodiesterase	B:C1452465
10	I:C1452465
loss	O
may	O
represent	O
a	O
homeostatic	O
adaptation	O
to	O
maintain	O
signaling	O
.	O

Cyclic	O
nucleotide	I:C1155588
signaling	I:C1155588
is	O
impaired	O
in	O
Huntington	O
's	I:C0020179
disease	I:C0020179
models	O
,	O
and	O
phoshodiesterase	O
10	I:C1452465
loss	O
may	O
represent	O
a	O
homeostatic	B:C0019868
adaptation	O
to	O
maintain	O
signaling	O
.	O

Cyclic	O
nucleotide	I:C1155588
signaling	I:C1155588
is	O
impaired	O
in	O
Huntington	O
's	I:C0020179
disease	I:C0020179
models	O
,	O
and	O
phoshodiesterase	O
10	I:C1452465
loss	O
may	O
represent	O
a	O
homeostatic	O
adaptation	B:C0392673
to	O
maintain	O
signaling	O
.	O

Cyclic	O
nucleotide	I:C1155588
signaling	I:C1155588
is	O
impaired	O
in	O
Huntington	O
's	I:C0020179
disease	I:C0020179
models	O
,	O
and	O
phoshodiesterase	O
10	I:C1452465
loss	O
may	O
represent	O
a	O
homeostatic	O
adaptation	O
to	O
maintain	O
signaling	B:C3537152
.	O

Elevation	B:C0439775
of	O
both	O
cAMP	O
and	O
cGMP	O
by	O
phoshodiesterase	O
10	I:C1452465
inhibition	O
was	O
required	O
for	O
rescue	O
.	O

Elevation	O
of	O
both	O
cAMP	B:C0001455
and	O
cGMP	O
by	O
phoshodiesterase	O
10	I:C1452465
inhibition	O
was	O
required	O
for	O
rescue	O
.	O

Elevation	O
of	O
both	O
cAMP	O
and	O
cGMP	B:C0018338
by	O
phoshodiesterase	O
10	I:C1452465
inhibition	O
was	O
required	O
for	O
rescue	O
.	O

Elevation	O
of	O
both	O
cAMP	O
and	O
cGMP	O
by	O
phoshodiesterase	B:C1452465
10	I:C1452465
inhibition	O
was	O
required	O
for	O
rescue	O
.	O

Phosphoproteomic	B:C1327760
profiling	I:C1327760
of	O
striatum	O
in	O
response	O
to	O
phoshodiesterase	O
10	I:C1452465
inhibition	O
highlighted	O
plausible	O
neural	O
substrates	O
responsible	O
for	O
the	O
improvement	O
.	O

Phosphoproteomic	O
profiling	I:C1327760
of	O
striatum	B:C0229962
in	O
response	O
to	O
phoshodiesterase	O
10	I:C1452465
inhibition	O
highlighted	O
plausible	O
neural	O
substrates	O
responsible	O
for	O
the	O
improvement	O
.	O

Phosphoproteomic	O
profiling	I:C1327760
of	O
striatum	O
in	O
response	O
to	O
phoshodiesterase	B:C1452465
10	I:C1452465
inhibition	O
highlighted	O
plausible	O
neural	O
substrates	O
responsible	O
for	O
the	O
improvement	O
.	O

Early	O
chronic	O
phoshodiesterase	B:C1452465
10	I:C1452465
inhibition	O
in	O
Q175	O
mice	I:C2986594
showed	O
improvements	O
beyond	O
those	O
seen	O
with	O
acute	O
administration	O
after	O
symptom	O
onset	O
,	O
including	O
partial	O
reversal	O
of	O
striatal	O
deregulated	O
transcripts	O
and	O
the	O
prevention	O
of	O
the	O
emergence	O
of	O
Huntington	O
's	I:C0020179
disease	I:C0020179
neurophysiological	O
deficits	O
.	O

Early	O
chronic	O
phoshodiesterase	O
10	I:C1452465
inhibition	O
in	O
Q175	B:C2986594
mice	I:C2986594
showed	O
improvements	O
beyond	O
those	O
seen	O
with	O
acute	O
administration	O
after	O
symptom	O
onset	O
,	O
including	O
partial	O
reversal	O
of	O
striatal	O
deregulated	O
transcripts	O
and	O
the	O
prevention	O
of	O
the	O
emergence	O
of	O
Huntington	O
's	I:C0020179
disease	I:C0020179
neurophysiological	O
deficits	O
.	O

Early	O
chronic	O
phoshodiesterase	O
10	I:C1452465
inhibition	O
in	O
Q175	O
mice	I:C2986594
showed	O
improvements	O
beyond	O
those	O
seen	O
with	O
acute	O
administration	B:C1533734
after	O
symptom	O
onset	O
,	O
including	O
partial	O
reversal	O
of	O
striatal	O
deregulated	O
transcripts	O
and	O
the	O
prevention	O
of	O
the	O
emergence	O
of	O
Huntington	O
's	I:C0020179
disease	I:C0020179
neurophysiological	O
deficits	O
.	O

Early	O
chronic	O
phoshodiesterase	O
10	I:C1452465
inhibition	O
in	O
Q175	O
mice	I:C2986594
showed	O
improvements	O
beyond	O
those	O
seen	O
with	O
acute	O
administration	O
after	O
symptom	B:C1457887
onset	O
,	O
including	O
partial	O
reversal	O
of	O
striatal	O
deregulated	O
transcripts	O
and	O
the	O
prevention	O
of	O
the	O
emergence	O
of	O
Huntington	O
's	I:C0020179
disease	I:C0020179
neurophysiological	O
deficits	O
.	O

Early	O
chronic	O
phoshodiesterase	O
10	I:C1452465
inhibition	O
in	O
Q175	O
mice	I:C2986594
showed	O
improvements	O
beyond	O
those	O
seen	O
with	O
acute	O
administration	O
after	O
symptom	O
onset	O
,	O
including	O
partial	O
reversal	O
of	O
striatal	B:C0229962
deregulated	O
transcripts	O
and	O
the	O
prevention	O
of	O
the	O
emergence	O
of	O
Huntington	O
's	I:C0020179
disease	I:C0020179
neurophysiological	O
deficits	O
.	O

Early	O
chronic	O
phoshodiesterase	O
10	I:C1452465
inhibition	O
in	O
Q175	O
mice	I:C2986594
showed	O
improvements	O
beyond	O
those	O
seen	O
with	O
acute	O
administration	O
after	O
symptom	O
onset	O
,	O
including	O
partial	O
reversal	O
of	O
striatal	O
deregulated	O
transcripts	B:C1519595
and	O
the	O
prevention	O
of	O
the	O
emergence	O
of	O
Huntington	O
's	I:C0020179
disease	I:C0020179
neurophysiological	O
deficits	O
.	O

Early	O
chronic	O
phoshodiesterase	O
10	I:C1452465
inhibition	O
in	O
Q175	O
mice	I:C2986594
showed	O
improvements	O
beyond	O
those	O
seen	O
with	O
acute	O
administration	O
after	O
symptom	O
onset	O
,	O
including	O
partial	O
reversal	O
of	O
striatal	O
deregulated	O
transcripts	O
and	O
the	O
prevention	O
of	O
the	O
emergence	O
of	O
Huntington	B:C0020179
's	I:C0020179
disease	I:C0020179
neurophysiological	O
deficits	O
.	O

Early	O
chronic	O
phoshodiesterase	O
10	I:C1452465
inhibition	O
in	O
Q175	O
mice	I:C2986594
showed	O
improvements	O
beyond	O
those	O
seen	O
with	O
acute	O
administration	O
after	O
symptom	O
onset	O
,	O
including	O
partial	O
reversal	O
of	O
striatal	O
deregulated	O
transcripts	O
and	O
the	O
prevention	O
of	O
the	O
emergence	O
of	O
Huntington	O
's	I:C0020179
disease	I:C0020179
neurophysiological	B:C1327471
deficits	O
.	O

